Michelle A Petri

List of Publications by Citations

Source: https://exaly.com/author-pdf/7870857/michelle-a-petri-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

313 papers

26,108 citations

78 h-index

157 g-index

356 ext. papers

31,948 ext. citations

6.1 avg, IF

6.98 L-index

#	Paper	IF	Citations
313	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2677-86		2688
312	The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996 , 39, 363-9		1688
311	Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2011 , 377, 721-31	40	1206
310	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3918-30		944
309	Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. <i>New England Journal of Medicine</i> , 2005 , 353, 2219-28	59.2	789
308	Combined oral contraceptives in women with systemic lupus erythematosus. <i>New England Journal of Medicine</i> , 2005 , 353, 2550-8	59.2	742
307	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1997 , 40, 809-13		505
306	Risk factors for coronary artery disease in patients with systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1992 , 93, 513-9	2.4	501
305	A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1168-78		424
304	Hydroxychloroquine in lupus pregnancy. Arthritis and Rheumatism, 2006, 54, 3640-7		362
303	Damage in systemic lupus erythematosus and its association with corticosteroids. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1801-8		352
302	Novel evidence-based systemic lupus erythematosus responder index. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1143-51		318
301	Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. <i>Lancet, The</i> , 1996 , 348, 1120-4	40	315
300	Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. <i>Immunity</i> , 2018 , 49, 725-739.e6	32.3	303
299	Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2453-9		300
298	The impact of increased lupus activity on obstetric outcomes. <i>Arthritis and Rheumatism</i> , 2005 , 52, 514-2	1	290
297	Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. <i>Annals of Internal Medicine</i> , 2015 , 163, 153-63	8	264

296	Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. <i>Arthritis and Rheumatism</i> , 1991 , 34, 1538-45		263
295	Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1343-9	2.4	261
294	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019 , 20, 902-914	19.1	254
293	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1706-13	2.4	250
292	Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. <i>American Journal of Medicine</i> , 1994 , 96, 254-9	2.4	250
291	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018 , 392, 222-231	40	243
290	Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2311-8		236
289	Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 849-57		236
288	Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. <i>Arthritis and Rheumatism</i> , 1991 , 34, 937-44		234
287	Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. <i>Annals of Internal Medicine</i> , 2005 , 142, 620-6	8	225
286	Predictors of survival in systemic lupus erythematosus. <i>Medicine (United States)</i> , 2006 , 85, 147-156	1.8	212
285	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016 , 55, 252-62	3.9	210
284	Epidemiology of systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002 , 16, 847-58	5.3	205
283	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013 , 42, 130-5	15.5	194
282	Sifalimumab, a human anti-interferon-Emonoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1011-21		193
281	Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. <i>American Journal of Epidemiology</i> , 2012 , 176, 708-19	3.8	192
280	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Autoimmunity Reviews</i> , 2014 , 13, 917-30	13.6	186
279	The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin	8	185

278	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175
277	Systemic lupus erythematosus: Diagnosis and clinical management. <i>Journal of Autoimmunity</i> , 2019 , 96, 1-13	15.5	175
276	End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. <i>Arthritis and Rheumatology</i> , 2014 , 66, 390-6	9.5	174
275	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017 , 8, 16021	17.4	171
274	Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. <i>Medicine (United States)</i> , 1992 , 71, 291-302	1.8	170
273	Percutaneous vertebroplasty treatment of steroid-induced osteoporotic compression fractures. <i>Arthritis and Rheumatism</i> , 1998 , 41, 171-5		167
272	Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2774-82		164
271	Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. <i>Arthritis and Rheumatism</i> , 2012 , 64, 4021-8		162
270	Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2342-9		157
269	Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four women. <i>Arthritis and Rheumatism</i> , 1987 , 30, 601-6		154
268	Prednisone, lupus activity, and permanent organ damage. <i>Journal of Rheumatology</i> , 2009 , 36, 560-4	4.1	145
267	Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996 , 39, 2046-51		144
266	Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. <i>Current Rheumatology Reports</i> , 2011 , 13, 77-80	4.9	143
265	A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans. <i>Arthritis and Rheumatism</i> , 1997 , 40, 2207-11		138
264	The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. <i>Autoimmunity Reviews</i> , 2015 , 14, 401-14	13.6	136
263	Assessing disease activity in SLE patients during pregnancy. <i>Lupus</i> , 1999 , 8, 677-84	2.6	135
262	Epidemiology of systemic lupus erythematosus: an update. <i>Current Opinion in Rheumatology</i> , 2018 , 30, 144-150	5.3	134
261	Management strategies and future directions for systemic lupus erythematosus in adults. <i>Lancet, The,</i> 2019 , 393, 2332-2343	40	132

(2000-2002)

260	erythematosus: a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1820-9		132
259	Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2009 , 36, 1195-9	4.1	131
258	Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. <i>Arthritis and Rheumatism</i> , 1995 , 8, 137-45		131
257	High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003 , 48, 166-73		128
256	A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2350-7		128
255	Patterns of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2682-	8	128
254	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , 2017 , 69, 362-375	9.5	125
253	Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2002 , 29, 2531-6	4.1	124
252	The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1813-8		121
251	Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2143-53		119
250	Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2014 , 41, 300-9	4.1	118
249	Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1865-71		101
248	Oral contraceptives and systemic lupus erythematosus. Arthritis and Rheumatism, 1997, 40, 797-803		99
247	Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. <i>Journal of Rheumatology</i> , 2015 , 42, 2092-7	4.1	98
246	Self-reactive IgE exacerbates interferon responses associated with autoimmunity. <i>Nature Immunology</i> , 2016 , 17, 196-203	19.1	98
245	Review of classification criteria for systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 245-54, vi	2.4	97
244	Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 214, 108.e1-108.e14	6.4	96
243	Hopkins Lupus Cohort. 1999 update. <i>Rheumatic Disease Clinics of North America</i> , 2000 , 26, 199-213, v	2.4	91

242	The SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAs. <i>PLoS ONE</i> , 2014 , 9, e93846	3.7	91
241	Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2015 , 2, e000066	4.6	86
240	The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. <i>Thrombosis Research</i> , 2004 , 114, 593-5	8.2	85
239	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 138-42	2.4	83
238	Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 2859-70	12.7	83
237	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 543-546	2.4	80
236	Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2010 , 37, 2032-8	4.1	79
235	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1837-47	9.5	77
234	PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. <i>JCI Insight</i> , 2019 , 4,	9.9	76
233	The Hopkins Lupus Pregnancy Center: ten key issues in management. <i>Rheumatic Disease Clinics of North America</i> , 2007 , 33, 227-35, v	2.4	75
232	Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 549-555	2.4	73
231	Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. <i>Blood</i> , 2020 , 135, 239-251	2.2	72
230	Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. <i>Lupus Science and Medicine</i> , 2016 , 3, e000131	4.6	72
229	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 534-542	2.4	71
228	Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. <i>Arthritis Care and Research</i> , 2016 , 68, 66-71	4.7	71
227	Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1790-1795	9.5	68
226	Renal biopsy in lupus patients with low levels of proteinuria. <i>Journal of Rheumatology</i> , 2007 , 34, 332-5	4.1	68
225	Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. <i>Journal of Rheumatology</i> , 2009 , 36, 82-8	4.1	67

224	Immunosuppressive drug use in pregnancy. <i>Autoimmunity</i> , 2003 , 36, 51-6	3	67
223	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2887-97		65
222	Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006 , 33, 1775-9	4.1	65
221	Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. <i>Rheumatology</i> , 2011 , 50, 2071-9	3.9	61
220	The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. <i>Arthritis and Rheumatism</i> , 2001 , 44, 389-96		61
219	The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2007 , 123, 74-81	9	60
218	Remission in systemic lupus erythematosus: durable remission is rare. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 547-553	2.4	59
217	Association of IgA Anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2011 , 38, 64-8	4.1	59
216	Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. <i>Journal of Rheumatology</i> , 2015 , 42, 2288-95	4.1	58
215	Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 855-860	2.4	55
214	Systemic Lupus Erythematosus and Pregnancy. <i>Rheumatic Disease Clinics of North America</i> , 2017 , 43, 215-226	2.4	54
213	Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. <i>Journal of Rheumatology</i> , 2004 , 31, 1557-9	4.1	54
212	Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. <i>Lupus Science and Medicine</i> , 2014 , 1, e000031	4.6	53
211	Stratification of Systemic Lupus Erythematosus Patients Into Three Groups of Disease Activity Progression According to Longitudinal Gene Expression. <i>Arthritis and Rheumatology</i> , 2018 , 70, 2025-20)3§·5	53
210	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1530-6	2.4	51
209	Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. <i>Arthritis and Rheumatology</i> , 2020 , 72, 448-453	9.5	50
208	Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. <i>American Journal of Human Genetics</i> , 2014 , 94, 586-98	11	49
207	Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1784-8		49

206	Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. <i>Journal of Rheumatology</i> , 2009 , 36, 2476-80	4.1	47
205	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 893-902	4.7	46
204	Predictors of incident depression in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2014 , 41, 1823-33	4.1	46
203	Evaluation of TRAF6 in a large multiancestral lupus cohort. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1960-9		45
202	Atherosclerosis in systemic lupus erythematosus. <i>Journal of Cardiovascular Pharmacology</i> , 2013 , 62, 255	5-62	45
201	Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy. <i>Journal of Rheumatology</i> , 2016 , 43, 745-50	4.1	42
200	European genetic ancestry is associated with a decreased risk of lupus nephritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3374-82		42
199	Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1125-1134	9.5	41
198	Hair product use in systemic lupus erythematosus. A case-control study. <i>Arthritis and Rheumatism</i> , 1992 , 35, 625-9		41
197	Longitudinal analysis of peripheral blood T cell receptor diversity in patients with systemic lupus erythematosus by next-generation sequencing. <i>Arthritis Research and Therapy</i> , 2015 , 17, 132	5.7	40
196	Disease activity assessment in SLE: do we have the right instruments?. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66 Suppl 3, iii61-4	2.4	40
195	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 464-4	<i>€</i> 8³	38
194	A quantitative lateral flow assay to detect complement activation in blood. <i>Analytical Biochemistry</i> , 2015 , 477, 78-85	3.1	38
193	High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1487-93		37
192	Management of antiphospholipid syndrome in pregnancy. <i>Rheumatic Disease Clinics of North America</i> , 2006 , 32, 591-607	2.4	37
191	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1478-1487	4.7	36
190	Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2013 , 40, 282-6	4.1	36
189	Cognitive function in a systemic lupus erythematosus inception cohort. <i>Journal of Rheumatology</i> , 2008 , 35, 1776-81	4.1	35

(2018-2017)

188	Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2017 , 4, e000192	4.6	34	
187	Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. <i>Arthritis and Rheumatology</i> , 2017 , 69, 643-	-634	34	
186	Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy. <i>Journal of Experimental Medicine</i> , 2019 , 216, 1154-1169	16.6	33	
185	Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study. <i>Journal of Proteome Research</i> , 2016 , 15, 2102-14	5.6	32	
184	Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. <i>American Journal of Human Genetics</i> , 2015 , 96, 731-9	11	31	
183	The Role of MicroRNAs and Human Epidermal Growth Factor Receptor 2 in Proliferative Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2415-26	9.5	31	
182	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 281-289	9.5	31	
181	Seasonal variation in the activity of systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012 , 39, 1392-8	4.1	29	
180	Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2184-92	9.5	29	
179	PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjgren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1145-51	2.4	28	
178	3' polymorphisms of ETS1 are associated with different clinical phenotypes in SLE. <i>Human Mutation</i> , 2000 , 16, 49-53	4.7	28	
177	Development of Biomarker Models to Predict Outcomes in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1955-63	9.5	27	
176	Associates and predictors of pleurisy or pericarditis in SLE. <i>Lupus Science and Medicine</i> , 2017 , 4, e00022	14.6	27	
175	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1932-44	9.5	27	
174	Association of Antibodies to Interferon-Inducible Protein-16 With Markers of More Severe Disease in Primary Sjgren's Syndrome. <i>Arthritis Care and Research</i> , 2016 , 68, 254-60	4.7	27	
173	Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis. <i>Rheumatology</i> , 2015 , 54, 1976-81	3.9	26	
172	H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus. <i>Clinical Epigenetics</i> , 2016 , 8, 14	7.7	26	
171	Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. <i>Arthritis Research and Therapy</i> , 2018 , 20, 133	5.7	26	

170	Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. <i>PLoS ONE</i> , 2014 , 9, e112545	3.7	26
169	Noncalcified coronary plaque in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2010 , 37, 57	9-8 4 1	25
168	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. <i>Arthritis and Rheumatology</i> , 2019 , 71, 411-419	9.5	25
167	Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. <i>BMC Medical Genomics</i> , 2019 , 12, 4	3.7	25
166	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 1074-1082	6.1	24
165	Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss. <i>Lupus Science and Medicine</i> , 2015 , 2, e000095	4.6	24
164	Development of a systemic lupus erythematosus cardiovascular risk equation. <i>Lupus Science and Medicine</i> , 2019 , 6, e000346	4.6	24
163	Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. <i>Journal of Rheumatology</i> , 2006 , 33, 57-60	4.1	24
162	Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. <i>Lupus Science and Medicine</i> , 2019 , 6, e000318	4.6	23
161	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 393-396	4.1	23
160	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. <i>Human Molecular Genetics</i> , 2018 , 27, 3813-3824	5.6	23
159	Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort. <i>Arthritis Care and Research</i> , 2012 , 64, 704-12	4.7	23
158	Integrated urine proteomics and renal single-cell genomics identify an IFN-Iresponse gradient in lupus nephritis. <i>JCI Insight</i> , 2020 , 5,	9.9	23
157	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019 , 71, 134-141	4.7	23
156	Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. <i>Journal of Rheumatology</i> , 2008 , 35, 1567-75	4.1	23
155	Risk factors for cataracts in systemic lupus erythematosus (SLE). <i>Rheumatology International</i> , 2015 , 35, 701-8	3.6	22
154	Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis. <i>Journal of Rheumatology</i> , 2018 , 45, 671-677	4.1	22
153	A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. <i>Human Molecular Genetics</i> , 2018 , 27, 2392-2404	5.6	22

152	Low frequency of flares during pregnancy and post-partum in stable lupus patients. <i>Arthritis Research and Therapy</i> , 2020 , 22, 52	5.7	21
151	Prevention and management of co-morbidities in SLE. <i>Presse Medicale</i> , 2014 , 43, e187-95	2.2	21
150	Multiplex giant magnetoresistive biosensor microarrays identify interferon-associated autoantibodies in systemic lupus erythematosus. <i>Scientific Reports</i> , 2016 , 6, 27623	4.9	21
149	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020 , 47, 72-81	4.1	21
148	Monocyte enhancers are highly altered in systemic lupus erythematosus. <i>Epigenomics</i> , 2015 , 7, 921-35	4.4	20
147	Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. <i>Nature Communications</i> , 2020 , 11, 2197	17.4	20
146	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018 , 57, 677-687	3.9	20
145	Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. <i>Lupus Science and Medicine</i> , 2016 , 3, e000107	4.6	20
144	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 374-382	6.1	20
143	Pregnancy and Systemic Lupus Erythematosus. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020 , 64, 24-30	4.6	20
142	Semiquantified noncalcified coronary plaque in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012 , 39, 2286-93	4.1	19
141	Clinical significance and correlations between anti-2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus. <i>Clinica Chimica Acta</i> , 2016 , 460, 107-13	6.2	19
140	Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018 , 70, 230-235	4.7	18
139	Systemic lupus erythematosus: 2006 update. <i>Journal of Clinical Rheumatology</i> , 2006 , 12, 37-40	1.1	18
138	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 356-362	2.4	18
137	Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1964-9	9.5	18
136	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020 , 72, 67-77	9.5	18
135	American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. <i>Journal of Rheumatology</i> , 2014 , 41, 875-80	4.1	17

134	The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years?. <i>Current Treatment Options in Rheumatology</i> , 2017 , 3, 164-172	1.3	17
133	Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus. <i>Rheumatology International</i> , 2015 , 35, 1687-92	3.6	16
132	Predictors of Incident Seizure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2016 , 43, 565	5-47.5	16
131	SLE-key(\square) rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP(\square). <i>Journal of Immunological Methods</i> , 2016 , 429, 1-6	2.5	16
130	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1297-1307	9.5	15
129	BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year. <i>Lupus Science and Medicine</i> , 2015 , 2, e000063	4.6	15
128	Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1789-95		15
127	Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus. <i>JCI Insight</i> , 2020 , 5,	9.9	15
126	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020 , 106, 102340	15.5	15
125	An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort. <i>Rheumatology</i> , 2015 , 54, 623-32	3.9	14
124	Antiphospholipid syndrome. <i>Translational Research</i> , 2020 , 225, 70-81	11	14
123	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. <i>Lupus Science and Medicine</i> , 2018 , 5, e000263	4.6	14
122	Progression of noncalcified and calcified coronary plaque by CT angiography in SLE. <i>Rheumatology International</i> , 2017 , 37, 59-65	3.6	14
121	Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [C]DPA-713 positron emission tomography. <i>Lupus</i> , 2017 , 26, 170-178	2.6	14
120	Bubcortical@ognitive impairment in patients with systemic lupus erythematosus. <i>Journal of the International Neuropsychological Society</i> , 2000 , 6, 821-825	3.1	14
119	Fatigue Measurements in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019 , 46, 1470-147	74.1	14
118	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	14
117	Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages. <i>Frontiers in Immunology</i> , 2020 , 11, 671	8.4	13

(2007-2020)

116	Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. <i>Arthritis Care and Research</i> , 2020 ,	4.7	13
115	Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1349-1361	2.4	13
114	The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA. <i>PLoS ONE</i> , 2016 , 11, e0161818	3.7	13
113	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018 , 70, 1294-1302	4.7	13
112	Predictors of incident proteinuria among patients with SLE. <i>Lupus Science and Medicine</i> , 2017 , 4, e00020	10 4.6	12
111	High-Resolution Analysis of Antibodies to Post-Translational Modifications Using Peptide Nanosensor Microarrays. <i>ACS Nano</i> , 2016 , 10, 10652-10660	16.7	12
110	Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 2007-2013	2.4	12
109	Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification. <i>Scientific Reports</i> , 2019 , 9, 15502	4.9	12
108	Treatment of the antiphospholipid antibody syndrome: progress in the last five years?. <i>Current Rheumatology Reports</i> , 2000 , 2, 256-61	4.9	12
107	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020 , 961203320940776	2.6	12
106	Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America. <i>Lupus Science and Medicine</i> , 2019 , 6, e000317	4.6	11
105	SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus. <i>Scientific Reports</i> , 2019 , 9, 14433	4.9	11
104	Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2018 , 5, e000237	4.6	11
103	Significance of Lipid-Derived Reactive Aldehyde-Specific Immune Complexes in Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2016 , 11, e0164739	3.7	11
102	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020 , 72, 658-666	9.5	11
101	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1231-1235	4.7	10
100	Performance Characteristics of Commercial Immunoassays for the Detection of IgG and IgM Antibodies to I Glycoprotein I and an Initial Assessment of Newly Developed Reference Materials for Assay Calibration. <i>American Journal of Clinical Pathology</i> , 2016 , 145, 796-805	1.9	10
99	Monitoring systemic lupus erythematosus in standard clinical care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007 , 21, 687-97	5.3	10

98	Pericarditis in Lupus. <i>Cureus</i> , 2019 , 11, e4166	1.2	10
97	Enhancer RNA and NF B -dependent P300 regulation of ADAMDEC1. <i>Molecular Immunology</i> , 2018 , 103, 312-321	4.3	10
96	Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. <i>Arthritis Research and Therapy</i> , 2018 , 20, 36	5.7	9
95	The SLE-key test serological signature: new insights into the course of lupus. <i>Rheumatology</i> , 2018 , 57, 1632-1640	3.9	9
94	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 242-52	2.4	8
93	Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1468-1477	4.3	8
92	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2015 , 161, 157-62	9	8
91	A Spatiotemporal Analysis of Organ-Specific Lupus Flares in Relation to Atmospheric Variables and Fine Particulate Matter Pollution. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1134-1142	9.5	8
90	Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. <i>Rheumatology</i> , 2018 , 57, 125-133	3.9	8
89	Evidence-based management of thrombosis in the antiphospholipid antibody syndrome. <i>Current Rheumatology Reports</i> , 2003 , 5, 370-3	4.9	8
88	Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity. <i>Arthritis Care and Research</i> , 2020 , 72, 225-232	4.7	8
87	New classification criteria for systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 590-596	5.3	8
86	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1734-1740	9.5	7
85	Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 176	5.7	7
84	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
83	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020 , 72, 1800-1808	4.7	7
82	Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 3770-3777	3.9	7
81	Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021 , 73, 997-1004	9.5	7

(2020-2021)

80	Risk Factors For Infection And Health Impacts Of The Covid-19 Pandemic In People With Autoimmune Diseases. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	7
79	Clinical Application of a Modular Genomics Technique in Systemic Lupus Erythematosus: Progress towards Precision Medicine. <i>International Journal of Genomics</i> , 2016 , 2016, 7862962	2.5	7
78	Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2018 , 5, e000287	4.6	7
77	IL-1 Transcriptional Responses to Lipopolysaccharides Are Regulated by a Complex of RNA Binding Proteins. <i>Journal of Immunology</i> , 2020 , 204, 1334-1344	5.3	6
76	Preconceptional Cardiovascular Health and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019 , 46, 70-77	4.1	6
75	Accuracy of creatinine clearance in measuring glomerular filtration rate in patients with systemic lupus erythematosus without clinical evidence of renal disease. <i>Arthritis and Rheumatism</i> , 1990 , 33, 277-	-80	6
74	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. <i>Arthritis Care and Research</i> , 2020 , 72, 233-242	4.7	6
73	Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e90	2.4	6
72	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019 , 58, 1259-1267	3.9	5
71	Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. <i>International Journal of Rheumatic Diseases</i> , 2011 , 14, 1-5	2.3	5
70	Predictors of osteonecrosis in systemic lupus erythematosus: A prospective cohort study. <i>Arthritis Care and Research</i> , 2020 ,	4.7	5
69	Autoantibody clustering of lupus-associated pulmonary hypertension. <i>Lupus Science and Medicine</i> , 2019 , 6, e000356	4.6	5
68	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	5
67	MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study. <i>Retina</i> , 2019 , 39, 485-491	3.6	4
66	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2069-2080	15.4	4
65	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4
64	High-risk coronary plaque in SLE: low-attenuation non-calcified coronary plaque and positive remodelling index. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	4
63	Cutaneous vasculitis in SLE. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	4

62	Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	4
61	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1010-1012	2.4	4
60	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021 , 48, 541-547	4.1	4
59	Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy. <i>Medicina (Lithuania)</i> , 2019 , 55,	3.1	3
58	Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	3
57	Deconvoluting virome-wide antibody epitope reactivity profiles <i>EBioMedicine</i> , 2021 , 75, 103747	8.8	3
56	Measures of Fatigue in Patients With Rheumatic Diseases: A Critical Review. <i>Arthritis Care and Research</i> , 2020 , 72 Suppl 10, 369-409	4.7	3
55	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. <i>Current Rheumatology Reports</i> , 2021 , 23, 45	4.9	3
54	Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020 , 47, 387-393	4.1	3
53	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) <i>Lupus</i> , 2021 , 9612033211062523	2.6	3
52	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020 ,	4.7	2
51	The polymorphic CYP17 allele is not found with increased frequency in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998 , 41, 940-1		2
50	The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses <i>Journal of Clinical Investigation</i> , 2022 , 132,	15.9	2
49	Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2019 , 2019, 415-420	3.1	2
48	Association of African-American ethnicity and smoking status with total and individual damage index in systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2020 , 39, 365-373	3.9	2
47	Classical complement activation on human erythrocytes in subjects with systemic lupus erythematosus and a history of autoimmune hemolytic anemia. <i>Lupus</i> , 2020 , 29, 1179-1188	2.6	2
46	Cachexia in Systemic Lupus Erythematosus: Risk Factors and Relation to Disease Activity and Damage. <i>Arthritis Care and Research</i> , 2021 , 73, 1577-1582	4.7	2
45	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021 , 73, 1789-1795	4.7	2

(2019-2020)

44	Glycosphingolipid-associated E1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	2
43	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021 , 30, 1283-1288	2.6	2
42	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2293-2302	9.5	2
41	185 Baricitinib-associated changes in type I interferon gene signature during a 24-week phase 2 clinical SLE trial 2019 ,		2
40	199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study 2019 ,		2
39	Risk of Renal Failure Within 10 or 20 Years of Systemic Lupus Erythematosus Diagnosis. <i>Journal of Rheumatology</i> , 2021 , 48, 222-227	4.1	2
38	RISK FACTORS FOR INFECTION AND HEALTH IMPACTS OF THE COVID-19 PANDEMIC IN PEOPLE WITH AUTOIMMUNE DISEASES 2021 ,		2
37	Response to: 'Remission in SLE: the duration depends on multiple factors, including the definition' by Doria et al. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e78	2.4	1
36	Anti-retinoblastoma Protein Antibodies: A New Specificity in Systemic Lupus Erythematosus Associated With Protection Against Lupus Nephritis. <i>ACR Open Rheumatology</i> , 2019 , 1, 287-291	3.5	1
35	Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery. <i>Lupus Science and Medicine</i> , 2019 , 6, e000335	4.6	1
34	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 287	5.7	1
33	Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients. <i>SAGE Open Medicine</i> , 2013 , 1, 2050312113514404	2.4	1
32	Biologics use in sle in 23 centers Idata from the international registry for biologics in SLE. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, A9.1-A9	2.4	1
31	Salivary anti-nuclear antibody (ANA) mirrors serum ANA in systemic lupus erythematosus <i>Arthritis Research and Therapy</i> , 2022 , 24, 3	5.7	1
30	Urine Proteomics and Renal Single Cell Transcriptomics Implicate IL-16 in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	1
29	Clinical Outcomes Observed among Biopsy Proven Lupus Nephritis Patients Treated with Mycophenolate Mofetil as First-line Therapy. <i>Cureus</i> , 2017 , 9, e1907	1.2	1
28	Pauci-immune Glomerulonephritis in Systemic Lupus Erythematosus (SLE). <i>Cureus</i> , 2018 , 10, e2949	1.2	1
27	Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic. <i>Blood</i> , 2019 , 134, 4-4	2.2	1

26	Loss of antiphospholipid antibody positivity post-thrombosis in SLE. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	1
25	Systemic lupus Erythematosus and geomagnetic disturbances: a time series analysis. <i>Environmental Health</i> , 2021 , 20, 28	6	1
24	Transcription Factor Activity Inference in Systemic Lupus Erythematosus. <i>Life</i> , 2021 , 11,	3	1
23	Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection. <i>Arthritis Research and Therapy</i> , 2021 , 23, 64	5.7	1
22	Rheumatoid Pachymeningitis: A Rare Complication of Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018 , 45, 1325-1326	4.1	1
21	Cerebral Venous Thrombosis Mimicking a Discrete Brain Mass: A Case Report and Literature Review. <i>Case Reports in Rheumatology</i> , 2018 , 2018, 5862912	0.8	1
20	Reply. Arthritis and Rheumatology, 2021 , 73, 2149-2150	9.5	1
19	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1139-1145	5.3	1
18	Treatment Patterns and Clinical Characteristics of Patients with Systemic Lupus Erythematosus and Musculoskeletal Symptoms: A Retrospective, Observational Study <i>Advances in Therapy</i> , 2022 , 1	4.1	1
17	Predictors of the start of declining eGFR in patients with systemic lupus erythematosus. <i>Lupus</i> , 2021 , 30, 15-24	2.6	O
16	Reply. Arthritis Care and Research, 2017 , 69, 454	4.7	
15	Dr. Durcan, et al reply. <i>Journal of Rheumatology</i> , 2016 , 43, 1255	4.1	
14	Reply. Arthritis and Rheumatology, 2018 , 70, 2099	9.5	
13	Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply. <i>Arthritis and Rheumatology</i> , 2014 , 66, 480	9.5	
12	HMG-CoA Reductase Inhibitors Do Not Ameliorate Progressive Atherogenic Changes In Human Macrophages Treated With Systemic Lupus Erythematosus Patient Plasma: Implications For Statin Use and Novel Insight Into Systemic Lupus Erythematosus. <i>FASEB Journal</i> , 2018 , 32, 813.5	0.9	
11	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. <i>Advances in Rheumatology</i> , 2021 , 61, 64	3	
10	- E2-Glycoprotein Antibodies Activate the Alternative Pathway of Complement in Antiphospholipid Antibody Syndrome. <i>Blood</i> , 2016 , 128, 3818-3818	2.2	
9	Rheumatologic Disorders in Pregnancy209-222		

LIST OF PUBLICATIONS

8	Reply. Arthritis and Rheumatology, 2020 , 72, 2166	9.5
7	Response to Dr Nikpour's letter. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e80	2.4
6	Response to: 'Postpartum breastfeeding status' by Betzold. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e38	2.4
5	Reply. Arthritis and Rheumatology, 2020 , 72, 694	9.5
4	Reply. Arthritis and Rheumatology, 2021 , 73, 359	9.5
3	Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials. <i>Rheumatology</i> , 2021 , 60, 5390-5396	3.9
2	A prescription for exercise in systemic lupus erythematosus <i>Lupus</i> , 2021 , 9612033211061060	2.6
1	Drug monitoring in systemic lupus erythematosus <i>Current Opinion in Pharmacology</i> , 2022 , 64, 102225	5.1